Acquisition History / Eris Lifesciences / Swiss Parenterals
Eris Lifesciences Acquires Swiss Parenterals
Announced August 2024 — $72.0M
What happened
Eris Lifesciences acquired a 51% equity stake in Ahmedabad-based Swiss Parenterals for Rs 637.50 crore, with its promoter group buying another 19% for Rs 237.50 crore to take the combined holding to 70%. Swiss Parenterals makes sterile injectables for emerging markets; Eris later agreed to absorb the residual 30% via a share swap.
- Acquirer
- Eris Lifesciences
- Target
- Swiss Parenterals
- Announced
- August 2024
- Price
- $72.0M
- Industry
- Injectable pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Eris Lifesciences acquire Swiss Parenterals?
Eris Lifesciences acquired Swiss Parenterals on August 2024. This was Eris Lifesciences's 1st publicly tracked acquisition out of 1 we have on record.
How much did Eris Lifesciences pay for Swiss Parenterals?
Eris Lifesciences paid $72.0M for Swiss Parenterals.
What does Swiss Parenterals do?
Eris Lifesciences acquired a 51% equity stake in Ahmedabad-based Swiss Parenterals for Rs 637.50 crore, with its promoter group buying another 19% for Rs 237.50 crore to take the combined holding to 70%. Swiss Parenterals makes sterile injectables for emerging markets; Eris later agreed to absorb the residual 30% via a share swap.
What other Injectable pharmaceuticals companies has Eris Lifesciences acquired?
Swiss Parenterals is Eris Lifesciences's only publicly tracked acquisition in Injectable pharmaceuticals so far.